Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome

European Review for Medical and Pharmacological Sciences

Volumn 11, Issue 2, 2007, Pages 119-127

  Gravante, Gianpiero ^c   Delogu, D ^a   Marianetti, M ^b   Trombetta, M ^a   Esposito, G ^b   Montone, A ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Drug reactions; Lyell syndrome; Steven Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALLOPURINOL; AMPHOTERICIN; ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ANTIPARASITIC AGENT; BROMHEXINE; CEFAMANDOLE; CEFTRIAXONE; COTRIMOXAZOLE; CREATINE; DEFLAZACORT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FLUCONAZOLE; FUROSEMIDE; HYALURONIC ACID; IMMUNOGLOBULIN; JALOSKIN; KETOPROFEN; METRONIDAZOLE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PHENOBARBITAL; PYRANTEL EMBONATE; SERTRALINE; SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOPTERIN;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; BACTERIAL INFECTION; BACTERIUM ISOLATION; BODY SURFACE; CASE MANAGEMENT; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CORNEA DISEASE; DEATH; DEEP VEIN THROMBOSIS; FATALITY; FEMALE; FLU LIKE SYNDROME; HISTOPATHOLOGY; HUMAN; LEISHMANIASIS; LEUKOCYTE COUNT; MALE; MORTALITY; MYELOID METAPLASIA; NONHODGKIN LYMPHOMA; PAIN; PLEURA MESOTHELIOMA; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SODIUM BLOOD LEVEL; STEVENS JOHNSON SYNDROME; SYMPTOM; TENSION HEADACHE; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34249749295     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. CHAVE TA, MORTIMER NJ, SLADDEN MJ, HALL AP, HUTCHINSON PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-253.
2. BECKER DS. Toxic epidermal necrolysis. Lancet 1998; 351: 1417-1420.
3. DUCIC I, SHALOM A, RISING W. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002; 110, 768.
4. HEIMBACH DM, ENGRAV LH, MARVIN JA, HARNAR TJ, GRUBE BJ. Toxic epidermal necrolysis. A step forward in treatment. JAMA 1987; 257: 2171-2175.
5. ZOLTIE N, VERLENDE P, O'NEILL TJ, MCKENZIE AW. Lyell's syndrome on a bums unit. Burns 1994; 20: 368-370.
6. GREEN D, LAW E, STILL JM. An approach to the management of toxic epidermal necrolysis in a bum centre. Burns 1993; 19: 411-414.
7. PALMIERI TL, GREENHALGH DG, SAFFLE JR, SPENCE RJ, PECK MD, JENG JC, MOZINGO DW, YOWLER CJ, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23: 87-96.
8. HETTIARATCHY S, MOLONEY D, CLARKE J. Patients with acute skin loss: are they best managed on a burns unit? Ann R Coll Surg Engl 2001; 83: 26-29.
9. KHOO AK, FOO CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996; 22: 275-278.
10. YING S, HO W, CHAN HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns 2001; 27: 372-375.
11. KELEMEN JJ 3RD, CIOFFI WG, MCMANUS WF, MASON AD JR, PRUITT BA Jr. Bum center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180: 273-278.
12. ROUJEAU JC, KELLY JP NALDI L, RZANY B, STERN RS, ANDERSON T, AUQUIER A, BASTUJI-GARIN S, CORREIA O, LOCATI F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
13. RZANY B, CORREIA O, KELLY JP, NALDI L, AUQUIER A, STERN R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353: 2190-2194.
14. BASTUJI-GARIN S, FOUCHARD N, BERTOCCHI M, ROUJEAU JC, REVUZ J, WOLKENSTEIN P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153.
15. GUEGAN S, BASTUJI-GARIN S, POSZEPCZYNSKA-GUIGNE E, ROUJEAU JC, REVUZ J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-276.
16. CHAN HL. Observations of drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol 1984; 10: 973-978.
17. RONJEAU JC, GUILLAUNE JC, FABRE JC. Toxic epidermal necrolysis (Lyell syndrome), incidence and drug etiology in France. Arch Dermatol 1990; 126: 37-42.
18. NALDI L, LOCATI L, MARCHESI L. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126: 1103-1104.
19. SCHOPF E, STUHMER A, RZANY B. Toxic epidermal necrolysis and Steven-Johnson syndrome; an epidemiological study from West Germany. Arch Dermatol 1990; 127: 839-847.
20. KIM PS, GOLDFARB IW, GAISFORD JC. Steven-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil 1983; 4: 91-100.
21. VIARD I, WEHRLI P, BULLANI R, SCHNEIDER P, HOLLER N, SALOMON D, HUNZIKER T, SAURAT JH, TSCHOPP J, FRENCH LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.